利敏舒联合氯雷他定治疗过敏性荨麻疹的临床作用分析
|
摘要
目的探讨利敏舒联合氯雷他定在过敏性荨麻疹患者中的临床作用。方法 62例过敏性荨麻疹患者,采用电脑抽取随机数法分为对照组和观察组,各31例。对照组患者给予氯雷他定治疗,观察组患者在对照组基础上联合利敏舒治疗,比较两组血清免疫球蛋白E(Ig E)、炎症因子、T淋巴细胞水平及不良反应发生情况。结果治疗前,两组患者血清IgE、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、白细胞介素-18(IL-18)水平比较,差异无统计学意义(P>0.05);治疗后3个月,两组患者血清IgE、IL-4、IL-10、IL-18水平均优于治疗前,且观察组血清IgE、IL-4、IL-10水平低于对照组, IL-18水平高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者CD3+、CD4+、CD8+、CD4+/CD8+比较,差异无统计学意义(P>0.05);治疗后3个月,两组患者CD3+、CD4+、CD8+、CD4+/CD8+均优于治疗前,且观察组患者CD3+、CD4+、CD4+/CD8+水平高于对照组(P<0.05);CD8+水平低于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后乏力、口干、恶心呕吐、腹泻、血压波动不良反应发生率分别为3.23%、0、3.23%、0、3.23%,对照组患者治疗后乏力、口干、恶心呕吐、腹泻、血压波动不良反应发生率分别为0、3.23%、6.45%、3.23%、6.45%,比较差异无统计学意义(P>0.05)。结论利敏舒联合氯雷他定治疗过敏性荨麻疹患者有助于改善血清IgE、T淋巴细胞水平,改善炎症因子水平,且联合用药未增加不良反应发生率,值得推广应用。
Objective To discuss the clinical effect of Liminshu combined with loratadine in the treatment of allergic urticaria. Methods A total of 62 allergic urticaria patients were divided into control group and observation group according to computer extraction of random numbers method, with 31 cases in each group. The control group was treated with loratadine, and the observation group was treated with Liminshu on the basis of the control group. Comparison were made on serum immunoglobulin E(IgE), inflammatory factors, T lymphocyte levels and occurrence of adverse reactions between the two groups. Results Before treatment, both groups had no statistically significant difference in serum IgE, interleukin-4(IL-4), interleukin-10(IL-10) and interleukin-18(IL-18)(P>0.05). After 3 months of treatment, both groups had better serum IgE, IL-4, IL-10 and IL-18 than those before treatment. The observation group had lower serum IgE, IL-4, IL-10 than the control group, and higher IL-18 than the control group. Their difference was statistically significant(P<0.05). Before treatment, both groups had no statistically significant difference in CD3~+, CD4~+, CD8~+ and CD4~+/CD8~+(P>0.05). After 3 months of treatment, both groups had better CD3~+, CD4~+, CD8~+ and CD4~+/CD8+ than those before treatment, and the observation group had better CD3~+, CD4~+, CD8~+ and CD4~+/CD8~+ than the control group(P<0.05), and lower CD8~+ than the control group. Their difference was statistically significant(P<0.05). After treatment, the observation group had incidence of adverse reactions to fatigue, dry mouth, nausea and vomiting, diarrhea and fluctuation of blood pressure respectively as 3.23%, 0, 3.23%, 0 and 3.23%, which were 0, 3.23%, 6.45%、3.23% and 6.45% in the control group, and their difference was not statistically significant(P>0.05). Conclusion For the treatment of allergic urticaria, Liminshu combined with loratadine is helpful to improve serum IgE and T lymphocyte level, and inflammatory factors level. Moreover, the combined medication does not increase the incidence of adverse reactions, and is worthy of promotion and application.
Objective To discuss the clinical effect of Liminshu combined with loratadine in the treatment of allergic urticaria. Methods A total of 62 allergic urticaria patients were divided into control group and observation group according to computer extraction of random numbers method, with 31 cases in each group. The control group was treated with loratadine, and the observation group was treated with Liminshu on the basis of the control group. Comparison were made on serum immunoglobulin E(IgE), inflammatory factors, T lymphocyte levels and occurrence of adverse reactions between the two groups. Results Before treatment, both groups had no statistically significant difference in serum IgE, interleukin-4(IL-4), interleukin-10(IL-10) and interleukin-18(IL-18)(P>0.05). After 3 months of treatment, both groups had better serum IgE, IL-4, IL-10 and IL-18 than those before treatment. The observation group had lower serum IgE, IL-4, IL-10 than the control group, and higher IL-18 than the control group. Their difference was statistically significant(P<0.05). Before treatment, both groups had no statistically significant difference in CD3~+, CD4~+, CD8~+ and CD4~+/CD8~+(P>0.05). After 3 months of treatment, both groups had better CD3~+, CD4~+, CD8~+ and CD4~+/CD8+ than those before treatment, and the observation group had better CD3~+, CD4~+, CD8~+ and CD4~+/CD8~+ than the control group(P<0.05), and lower CD8~+ than the control group. Their difference was statistically significant(P<0.05). After treatment, the observation group had incidence of adverse reactions to fatigue, dry mouth, nausea and vomiting, diarrhea and fluctuation of blood pressure respectively as 3.23%, 0, 3.23%, 0 and 3.23%, which were 0, 3.23%, 6.45%、3.23% and 6.45% in the control group, and their difference was not statistically significant(P>0.05). Conclusion For the treatment of allergic urticaria, Liminshu combined with loratadine is helpful to improve serum IgE and T lymphocyte level, and inflammatory factors level. Moreover, the combined medication does not increase the incidence of adverse reactions, and is worthy of promotion and application.
引文
[1]周顺龙,许恩超,邓雯,等.氯雷他定联合地氯雷他定治疗儿童慢性自发性荨麻疹的临床观察.中华皮肤科杂志,2017,50(1):46-48.
[2]由丽娜,陈丽蓉,宋国宏,等.足三里穴位自血疗法联合地氯雷他定治疗胆碱能性荨麻疹的临床观察.中国现代医学杂志,2016,26(17):72-74.
[3]Hong L,Du M,Mleczko MJ,et al.Kinetic Study of Hydrogen Evolution Reaction over Strained MoS2 with Sulfur Vacancies Using Scanning Electrochemical Microscopy.Journal of the American Chemical Society,2016,138(15):5123-5129.
[4]陈岚,陈辉,陈兴平,等.盐酸奥洛他定片治疗慢性特发性荨麻疹疗效和安全性的多中心临床研究.中国医院药学杂志,2017,37(16):1629-1634.
[5]萧毓萍.激光照射穴位结合氯雷他定口服治疗儿童过敏性鼻炎50例.中国中西医结合急救杂志,2016,23(6):657-658.
[6]高占梅,宋扬,刘华,等.氮卓斯汀鼻喷剂联合地氯雷他定治疗变应性鼻炎疗效的Meta分析.首都医科大学学报,2018,39(3):458-464.
[7]Badamo M,Casarona J,Zhao M,et al.Identifying Power-Efficient Multicore Cache Hierarchies via Reuse Distance Analysis.Acm Transactions on Computer Systems,2016,34(1):3.
[8]唐妮,毛曼云,翟睿,等.儿童荨麻疹与成人荨麻疹患者临床特征的比较分析.中国当代儿科杂志,2017,19(7):790-795.
[9]宋志强,罗娜,陈曙光,等.盐酸非索非那定片递减疗法治疗慢性自发性荨麻疹的疗效观察.中华皮肤科杂志,2016,49(8):547-550.
[10]唐政,瞿任,袁群霞,等.舌下含服脱敏治疗对伴尘螨致敏慢性自发性荨麻疹患者的疗效观察.重庆医学,2016,45(26):3650-3651.
[11]吴英桂,唐南仲,郑英巧.盐酸非索非那定片不同应用方案在慢性自发性荨麻疹患者中的效果对比.重庆医学,2017,46(32):4579-4581.
[12]邢春华,蔡育兵,丁菲,等.富马酸卢帕他定片治疗慢性特发性荨麻疹的有效性及安全性.中国医院药学杂志,2017,37(13):1271-1274.
[13]郭桂红,丁莉华,钟树文,等.蜂针联合氯雷他定胶囊治疗慢性荨麻疹疗效观察及护理.中国中医药现代远程教育,2016,14(5):117-119.
[14]Jang JH,Park SH,Jang HJ,et al.A Case of Recurrent Urticaria Due to Formaldehyde Release from Root-Canal Disinfectant.Yonsei Medical Journal,2017,58(1):252-254.
[15]Bongiorno MR,Crimi N,Corrao S,et al.Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice.Annals of Allergy Asthma&Immunology,2016,117(6):703.
[2]由丽娜,陈丽蓉,宋国宏,等.足三里穴位自血疗法联合地氯雷他定治疗胆碱能性荨麻疹的临床观察.中国现代医学杂志,2016,26(17):72-74.
[3]Hong L,Du M,Mleczko MJ,et al.Kinetic Study of Hydrogen Evolution Reaction over Strained MoS2 with Sulfur Vacancies Using Scanning Electrochemical Microscopy.Journal of the American Chemical Society,2016,138(15):5123-5129.
[4]陈岚,陈辉,陈兴平,等.盐酸奥洛他定片治疗慢性特发性荨麻疹疗效和安全性的多中心临床研究.中国医院药学杂志,2017,37(16):1629-1634.
[5]萧毓萍.激光照射穴位结合氯雷他定口服治疗儿童过敏性鼻炎50例.中国中西医结合急救杂志,2016,23(6):657-658.
[6]高占梅,宋扬,刘华,等.氮卓斯汀鼻喷剂联合地氯雷他定治疗变应性鼻炎疗效的Meta分析.首都医科大学学报,2018,39(3):458-464.
[7]Badamo M,Casarona J,Zhao M,et al.Identifying Power-Efficient Multicore Cache Hierarchies via Reuse Distance Analysis.Acm Transactions on Computer Systems,2016,34(1):3.
[8]唐妮,毛曼云,翟睿,等.儿童荨麻疹与成人荨麻疹患者临床特征的比较分析.中国当代儿科杂志,2017,19(7):790-795.
[9]宋志强,罗娜,陈曙光,等.盐酸非索非那定片递减疗法治疗慢性自发性荨麻疹的疗效观察.中华皮肤科杂志,2016,49(8):547-550.
[10]唐政,瞿任,袁群霞,等.舌下含服脱敏治疗对伴尘螨致敏慢性自发性荨麻疹患者的疗效观察.重庆医学,2016,45(26):3650-3651.
[11]吴英桂,唐南仲,郑英巧.盐酸非索非那定片不同应用方案在慢性自发性荨麻疹患者中的效果对比.重庆医学,2017,46(32):4579-4581.
[12]邢春华,蔡育兵,丁菲,等.富马酸卢帕他定片治疗慢性特发性荨麻疹的有效性及安全性.中国医院药学杂志,2017,37(13):1271-1274.
[13]郭桂红,丁莉华,钟树文,等.蜂针联合氯雷他定胶囊治疗慢性荨麻疹疗效观察及护理.中国中医药现代远程教育,2016,14(5):117-119.
[14]Jang JH,Park SH,Jang HJ,et al.A Case of Recurrent Urticaria Due to Formaldehyde Release from Root-Canal Disinfectant.Yonsei Medical Journal,2017,58(1):252-254.
[15]Bongiorno MR,Crimi N,Corrao S,et al.Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice.Annals of Allergy Asthma&Immunology,2016,117(6):703.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |